Monographie - Amphotericin B lipid complex

Последнее обновление :
29/10/2024

Amphotericin B lipid complex

Химическая структура

Товарное название

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Abelcet

Австралия, Австрия, Аргентина, Бельгия, Бразилия, Великобритания, Венгрия, Германия, Голландия, Греция, Дания, Ирландия, Испания, Италия, Канада, Люксембург, Малайзия, Мексика, Норвегия, Перу, Португалия, Румыния, Соединённые Штаты Америки, Финляндия, Франция, Швеция

Библиография : Amphotericin B lipid complex

	тип	публикация
1510	Книга	AHFS Formulary service 2000 Bethesda - 3546 p
2247	Журнал	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Журнал	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3254	Журнал	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Лаборатория	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3644	Лаборатория	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3828	плакат	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	плакат	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Журнал	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44

Mentions Légales